参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA:A Cancer Journal for Clinicians,2021,71(3):209-249.[2]Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chinese Medical Journal,2021,134(7):783-791.[3]Feng RM,Zong YN,Cao SM,et al.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Communications,2019,39(1):1-12. [4]尹周一,王梦圆,游伟程,等.2022美国癌症统计报告解读及中美癌症流行情况对比[J].肿瘤综合治疗电子杂志,2022,8(2):54-63.[5]张诗民,陈元,褚倩.免疫检查点抑制剂治疗肿瘤的不良反应及管理策略[J].中国肿瘤临床,2018,45(12):609-613.[6]魏筱,严文跃,吴慧,等.抗肿瘤中成药使用的影响因素分析[J].西北药学杂志,2021,36(2):310-314.[7]林洪生,李萍萍,薛冬,等.肿瘤姑息治疗中成药使用专家共识(2013版)[J].中国中西医结合杂志,2016,36(3):269-279.[8]周桢.中医药综合治疗175例Ⅲ-Ⅳ期非小细胞肺癌的回顾性研究及预后分析[D].上海:上海中医药大学,2016.[9]吕杨,刘晓琳,单探幽.不同中成药注射剂辅助治疗非小细胞肺癌的对比研究[J].中国医院用药评价与分析,2017,17(6):790-791,795.[10]胡洁,林丽珠,骆肖群,等.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志,2019,22(2):57-81.[11]廖伯年,赵研丽,蔡林,等.中医药对晚期非小细胞肺癌患者血清肿瘤标志物的干预作用[J].辽宁中医杂志,2017,44(1):96-99.[12]金丽玲.中药防护治疗方案联合化疗治疗非小细胞肺癌效果观察[J].内蒙古中医药,2016,35(11):95.[13]Wang D,Xu Y,Huang T,et al.Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation:A systematic review and meta-analysis[J].Phytomedicine,2022,104:154315.[14]封佳莉,李和根,周晓辉,等.中医药干预874例晚期非小细胞肺癌的生存分析[J].安徽中医药大学学报,2019,38(6):10-15.[15]Li K,Cheng H,Shen W,et al.Compound Taxus chinensis Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].Evidence-Based Complementary and Alternative Medicine,2021,2021:9535061.[16]Wang X,Liu Z,Sui X,et al.Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines[J].Phytomedicine,2019,59:152787.[17]王学谦,侯炜,郑佳彬,等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J].中医杂志,2020,61(8):690-694.[18]方园圆.复方斑蝥胶囊联合化疗治疗非小细胞肺癌的疗效及对患者免疫功能、化疗不良反应的影响[J].浙江中医杂志,2022,57(7):488-489.[19]本刊编辑部.《中国肿瘤临床》文章荐读：癌因性疲乏最新进展—NCCN(2018版）癌因性疲乏指南解读[J].中国肿瘤临床,2019,46(17):922.[20]张潇宇,谢晓冬.癌因性疲乏如何管理--2019NCCN癌症相关性疲乏指南解读[C]//2019年中国肿瘤标志物学术大会暨第十三届肿瘤标志物青年科学家论坛论文集. 2019.[21]《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗癌因性疲乏临床应用指南(2020年)[J].中国中西医结合杂志,2021,41(5):534-541.[22]李娜,陈信义,李潇,等.复方阿胶浆治疗癌因性疲乏的临床观察[J].中华中医药杂志,2013,28(2):565-567.[23]宋文佳.精元康胶囊治疗脾肾两虚型中晚期非小细胞肺癌患者癌因性疲乏的临床研究[D].郑州:河南中医药大学,2019.[24]Zhou Y,Zhao B,Wu W,et al.Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial[J].Trials,2018,19(1):474.[25]朱国胜,刘文静.浅析中医理论对癌性疼痛的认识[J].中医临床研究,2016,8(19):62-63.[26]樊碧发,侯丽,贾立群,等.癌痛规范化治疗中成药合理使用专家共识[J].中国疼痛医学杂志,2021,27(1):9-17.[27]闫京涛,李竹生,范宏宇.中医药治疗癌性发热的思路与方法[J].中医临床研究,2016,8(4):47-49.[28]Zhang P,Meng X,Tang X,et al.The effect of a coix seed oil injection on cancer pain relief.[J]. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,2018,27(2):461-465.[29]Zhao Z,Fan H,Higgins T,et al.Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways[J].Cancer Letters,2014,355(2):232-241.[30]邢丽菊.癌性发热的中西医认识和治疗[J].中医杂志,2011,52(11):924-926.[31]郭玉梅,李政霖,祁恒旭,等.血必净注射液治疗对晚期肺癌合并肺部感染患者血清炎性因子水平的影响[J].中国医药导报,2016,13(32):125-128.[32]杨李思瑞,田菲.肺一丸联合痰热清注射液治疗晚期非小细胞肺癌癌性发热30例疗效观察[J].湖南中医杂志,2019,35(8):51-52.[33]周宇姝,陈继欣,陈淑琪,等.紫龙金片联合化疗治疗非小细胞肺癌的荟萃分析[J].时珍国医国药,2021,32(4):809-815.[34]陈遐林,孙彩萍,王建芳.紫龙金片维持治疗晚期非小细胞肺癌患者的疗效观察[J].中国中西医结合杂志,2017,37(5):534-538.[35]孙彩萍,王建芳,陈遐林,等.紫龙金片联合化疗治疗晚期非小细胞肺癌的研究观察[J].中华中医药学刊,2015,33(5):1145-1147.[36]房芳,陈红,庞红梅,等.吉非替尼联合紫龙金片治疗中晚期非小细胞肺癌的临床观察[J].现代预防医学,2011,38(7):1346-1348.[37]滕华,孙宁宁,张利,等.紫龙金联合埃克替尼治疗表皮生长因子受体突变阳性晚期肺腺癌的疗效分析[J].中草药,2021,52(18):5643-5648.[38]王菲叶.基于真实世界中紫龙金片治疗晚期非小细胞肺癌的疗效及安全性分析[D].广州:广州中医药大学,2021.[39]杨爱莲,林锦培,林浩,等.紫龙金片治疗晚期恶性肿瘤临床观察[J].中草药,2018,49(16):3882-3884.[40]于同月,崔昊震,张松男,等.参一胶囊对晚期非小细胞肺癌临床化疗效果及免疫功能的影响分析[J].中国免疫学杂志,2018,34(7):1012-1016.[41]张英,王学谦,刘浩,等.参一胶囊联合化疗改善晚期非小细胞肺癌患者预后的多中心大样本随机临床研究[J].中华肿瘤杂志,2018,40(4):295-299.[42]张利诚,黄良龙,黄宽.参一胶囊联合化疗对中晚期非小细胞肺癌患者近期疗效及血清NKG2D、IFN-γ、IL-2水平和T淋巴细胞亚群的影响[J].中国老年学杂志,2020,40(11):2296-2299.[43]蒋锐沅,莫春梅,满婷婷,等.西黄丸对炎症微环境下肺癌A549荷瘤小鼠NLRP3炎症小体及其产物和肿瘤增殖的影响[J].中国实验方剂学杂志,2020,26(17):20-28.[44]胡彦辉,于卫江,耿良.威麦宁胶囊对肺癌化疗患者免疫功能及炎性微环境的影响[J].辽宁中医杂志,2019,46(3):538-541.[45]宋博.中成药辅助治疗晚期非小细胞肺癌的队列研究[D].天津:天津中医药大学,2021.[46]Li K,Cheng H,Shen W,et al.Compound Taxus chinensis Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].Evidence-Based Complementary and Alternative Medicine,2021,2021:9535061.[47]赵骏.复方斑蝥胶囊与吉非替尼联合对非小细胞肺癌患者疗效评价[J].中成药,2019,41(4):959-962.[48]Chen Y,Wu H,Wang X,et al.Huaier Granule extract inhibit the proliferation and metastasis of lung cancer cells through down-regulation of MTDH, JAK2/STAT3 and MAPK signaling pathways[J].Biomedicine Pharmacotherapy,2018,101:311-321.[49]江奋霞,徐爱国,张茜,等.贞芪扶正胶囊对晚期非小细胞肺癌患者免疫功能、生存质量、化疗不良反应的影响[J].现代中西医结合杂志,2019,28(35):3926-3929.[50]蒋晓芳,林山.扶正中药颗粒联合GC化疗方案对晚期非小细胞肺癌患者的免疫功能及近期疗效的影响分析[J].辽宁中医杂志,2017,44(4):809-811.[51]李光达,马云飞,张甘霖,等.固本消瘤胶囊加减方联合吉非替尼对非小细胞肺癌PC9与PC9GR细胞生物学行为的影响[J].中华中医药杂志,2021,36(6):3568-3571.[52]潘方舒,阙国勇.参丹散结胶囊联合奥希替尼治疗Ⅳ期非小细胞肺癌临床观察[J].浙江中西医结合杂志,2022,32(3):242-244.[53]周磊,邵燕儿,朱泽浩,等.华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学,2018,21(9):1047-1052.[54]裴帅,王勇智.分析非小细胞肺癌使用金龙胶囊联合放化疗治疗的效果[J].中国冶金工业医学杂志,2022,39(4):460-461.[55]梁素娇,严虹霞.复方苦参注射液辅助放化疗对肺癌患者免疫功能及VEGF、MMP-9水平的影响[J].光明中医,2020,35(16):2499-2502.[56]任玮.化疗联合康莱特软胶囊治疗晚期非小细胞肺癌的临床效果研究[J].黑龙江科学,2019,10(18):36-37.
相似文献/References:
[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,31(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Journal of Medical Information,2018,31(24):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹晓美,王莉娜.肺癌患者疾病不确定感的影响因素与干预措施研究现状[J].医学信息,2018,31(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Journal of Medical Information,2018,31(24):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]吴 倩,王一非.中西医结合治疗肺癌脑转移疗效与安全性的Meta分析[J].医学信息,2022,35(10):120.[doi:10.3969/j.issn.1006-1959.2022.10.029]
WU Qian,WANG Yi-fei.Meta-analysis of Efficacy and Safety of Integrated Traditional Chinese and Western Medicine in the Treatment of Brain Metastasis of Lung Cancer[J].Journal of Medical Information,2022,35(24):120.[doi:10.3969/j.issn.1006-1959.2022.10.029]
[4]王晓军.以时间护理为基础的呼吸训练与排痰管理对肺癌手术患者康复的影响研究[J].医学信息,2022,35(11):180.[doi:10.3969/j.issn.1006-1959.2022.11.048]
WANG Xiao-jun.Effect of Respiratory Training and Expectoration Management Based on Time Nursing on Rehabilitation of Patients with Lung Cancer Surgery[J].Journal of Medical Information,2022,35(24):180.[doi:10.3969/j.issn.1006-1959.2022.11.048]
[5]邢益辉,刘 曼,厉玛倩倩,等.快速康复对肺癌手术患者并发症发生及生活质量的影响研究[J].医学信息,2018,31(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Journal of Medical Information,2018,31(24):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[6]朱晓晓,张 顺,蔡 挺.镍暴露相关的肺癌发生分子机制研究[J].医学信息,2018,31(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Journal of Medical Information,2018,31(24):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[7]崔文君.血管紧张素Ⅱ受体拮抗剂联合中成药治疗
慢性肾炎蛋白尿的研究进展[J].医学信息,2018,31(17):45.[doi:10.3969/j.issn.1006-1959.2018.17.015]
CUI Wen-jun.Advances in Research of Angiotensin II Receptor Antagonist Combined with Chinese Patent Medicine in the Treatment of Chronic Nephritis Proteinuria[J].Journal of Medical Information,2018,31(24):45.[doi:10.3969/j.issn.1006-1959.2018.17.015]
[8]付云杰.肺癌患者血浆D-二聚体、NSE及CYFRA21-1联合检测的临床价值[J].医学信息,2018,31(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Journal of Medical Information,2018,31(24):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[9]覃柳麻,何慧敏.2014~2016年广西肿瘤医院肺癌患者流行病学及病理分布特征分析[J].医学信息,2019,32(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Journal of Medical Information,2019,32(24):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[10]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Journal of Medical Information,2019,32(24):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]